|
Nasus Pharma Ltd, a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, announced the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup, Inc. (collectively, Aptar), a leading global manufacturer of drug delivery systems, to support the ongoing clinical development and planned commercialization of NS002, Nasus Pharma's intranasal powder epinephrine product candidate.
Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructure.
"This collaboration represents a significant milestone for Nasus Pharma and for our NS002 programme," said Dan Teleman, chief executive officer of Nasus Pharma. "Through this collaboration, Nasus Pharma will secure a commercially proven Unit Dose System technology, providing us with a validated dosing infrastructure. This strategic relationship allows us to benefit from established regulatory pathways, manufacturing capabilities and supply chain, accelerating NS002's path to market while reducing development risks."
The collaboration establishes a comprehensive framework to support the development of NS002 through regulatory submissions with both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This strategic relationship provides Nasus with access to Aptar's technical expertise and manufacturing capabilities to advance NS002 through current clinical development to commercialization in alignment with Nasus Pharma's timeline and objectives.
|